Rigel Pharmaceuticals
RIGL
Get informed when a big investor buys or sells
+ FollowMarket Cap$608.9M
Close$
$-31.36
188.1% downside
Current Fair Value
188.1% downsideOvervalued by 188.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $608.90 Million |
|---|---|
| Enterprise Value | $630.21 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $20.4 |
| Beta | 1.18 |
| Outstanding Shares | 18,412,000 |
Return
| Return on Equity | 91.08% |
|---|---|
| Return on Assets | 72.18% |
| Return on Invested Capital | 29.72% |
Valuation & Multiples
| P/E Ratio | 1.66 |
|---|---|
| PEG | -6.82 |
| Price to Sales | 2.23 |
| Price to Book Ratio | 1.7 |
| Enterprise Value to Revenue | 2.1 |
| Enterprise Value to EBIT | 5.11 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 5, 2026
EPS Estimate
$0.74
Average shareholder expectationRevenue Estimate
$62.40 M
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$0.13
Average shareholder expectationRevenue Estimate
$56.12 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7432▲ 50.35% |
|---|---|
| Total Calls | 70,100▼ 59.22% |
| Total Puts | 52,100▲ 26.46% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 88.97%▼ 0.26% |
|---|---|
| Total Invested | $432.72M▼ 37.17% |
| Investors Holding | 155▼ 36.00% |
ESG Score
No data
About Rigel Pharmaceuticals
CEO: Raul Rodriguez